



Purpose: To study the effectiveness and safety of sibeprenlimab, an investigational drug for the treatment of IgAN (NCT05248646)1



~470 participants will be enrolled1



Multicenter: ~300 global sites in ~32 countries1





To find out more information on the trial, email the study team at visionary@otsuka-us.com


What is IgAN? (Berger's disease)

What is sibeprenlimab (sib-eh-pren-li-mab)?



kidney function IgA is a type of antibody that normally helps your body fight infection^{2,3}

- · In IgAN, an abnormal type of IgA is produced, which the body will consider foreign and attack^{3,4}
- · This leads to the formation of antibody clumps (complexes) in the kidney, causing damage^{3,4}





- APRIL is a protein that likely plays a key role in the formation of IgA. Patients with higher levels of APRIL may produce higher levels of abnormal IgA5-7
- Sibeprenlimab is a monoclonal antibody designed to block the activity of APRIL⁵
- Early studies have shown that sibeprenlimab can bind to APRIL, blocking its activity and reducing the production of abnormal IgA5
- Blocking the activity of APRIL may prevent further kidney damage in patients with IgAN5

Sibeprenlimab is an investigational drug in clinical studies; its effectiveness and safety have not been established

What does the VISIONARY trial involve?

Efficacy endpoint: To assess whether sibeprenlimab is effective at preventing further kidney damage using a measure called the urine protein to creatine ratio (uPCR)1

9 WEEKS

SCREENING1

Physical examination

and blood and urine

tests to see if you

can be in the study

Up to 9 weeks

before the start of

study intervention

26 MONTHS

2 MONTHS



Randomly assigned (assigning patients by chance to groups that receive different treatments)

You will receive sibeprenlimab or placebo in addition to your normal management

You will need to come back to the clinic/complete a home visit once a month for study drug administration and clinical tests

26 doses administered monthly in the clinic for 26 months as subcutaneous (under the skin) injections



END OF STUDY¹

You will need to come back to the clinic once a month for 2 months after the last dose of the study drug

You may be eligible to participate if you:1

- Are at least 18 years of age
- · Have been diagnosed with IgAN (by a kidney biopsy)



APRIL, A Proliferation-Inducing Ligand; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; OLE, open-label extension; SC, subcutaneous. 1. Otsuka Data on File, 2022. 2. He J-W et al. Theranostics. 2020;10:11462–11478. 3. IgA Nephropathy. National Institute of Diabetes and Digestive and Kidney Diseases. www.niddk.nih.gov/health-information/kidney-disease/iga-nephropathy. Accessed January 17, 2022. 4. Wyatt RJ and Julian BA. N Engl J Med. 2013;368:2402–2414. 5. Myette JR et al. Kidney Int. 2019;96:104–116. 6. Sallustio F et al. Nephrol Dial Transplant. 2021;36:452–464. 7. Han SS et al. J Am Soc Nephrol. 2016;27:3430–3439.



